Diethylstilbestrol (DES) syndrome is a reproductive health issue in women born to mothers who took the synthetic estrogen during pregnancy. It can cause vaginal and cervical cancers, infertility, and breast cancer. DES was used from the late 1930s to the 1980s to prevent miscarriages and stillbirths. Women born between 1940 and 1980 may be at risk for DES syndrome, and routine evaluations are necessary to catch breast cancers early. The complexity of conducting drug safety studies in pregnant women is illustrated by this public health issue.
Diethylstilbestrol (DES) syndrome is a group of reproductive health problems seen in women born to mothers who were prescribed DES during pregnancy. This synthetic estrogen was used from the late 1930s to the 1980s in an effort to prevent miscarriages and stillbirths. The researchers later realized that the DES daughters, as they are known, were more prone to certain reproductive health conditions due to their exposure to the drug during pregnancy. The use of DES in pregnant women is no longer standard due to these health risks.
Pregnant women exposed to DES are more at risk of vaginal and cervical cancers. They can also experience infertility and other reproductive tract-related issues as part of DES syndrome. Their incidence of breast cancer is higher than that of the general population. These abnormalities did not become immediately apparent until children born to mothers who took DES were grown up, by which time an entire generation had already been exposed to the drug.
Also, women who used DES during pregnancy have an increased risk of breast cancer. They do not experience the gynecological cancers associated with fetal exposure but need to receive routine evaluations for breast abnormalities to catch breast cancers early. These complications only became apparent later, as it can take decades for breast cancer to develop. As with other cancer-causing substances, DES has not been immediately linked to these problems, because epidemiologists have had to piece together different pieces of the puzzle to find the connection.
This public health issue illustrates the complexity of conducting drug safety studies in pregnant women. DES syndrome didn’t manifest itself until the drug had been in use for several decades, and there was no way to predict DES syndrome based on the original research that led to the drug’s approval. Monitoring drug complications after drugs are released to the open market is an important component of drug safety that allows healthcare professionals to identify emerging long-term complications as early as possible.
Women born between about 1940 and 1980 may be at risk for DES syndrome, depending on where they were born. Some nations phased out the use of this drug earlier than others. In cases where there are concerns about DES syndrome, the patient may need a more extensive diagnostic scan and evaluation than is recommended for the general population. This may include starting breast cancer screening earlier in life and getting Pap smears more regularly to identify early signs of cellular changes.
Protect your devices with Threat Protection by NordVPN
